SIMILAR PATTERN OF AMINO ACIDS MAPPED TO 'CHU'

List of Similar Pattern of Amino Acids

Hit pattern: 3D amino acid arrangements similar to known drug binding site
Query pattern: Residues from known binding site for annotated drug that match the hit pattern

(Click on the DrReposER ID to view details on interfaces and similar patterns of amino acids)
(Click on the view link on the last column to view superposed patterns of amino acids)

Filter list by:

	DrReposER ID / Desc.	Hit PDBID	Hit Macromolecule	Res. Matches	Interface	HETATM	RMSD	Dali Z-score	Seq. Identity (%)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1FMO_E_ADNE351_1 (CAMP-DEPENDENT PROTEIN KINASE)	3wig	DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (Homo sapiens)	7 / 12	LEU A 75 GLY A 76 VAL A 83 ALA A 96 VAL A 128 ASN A 196 LEU A 198	ANP A 401 (-3.8A) ANP A 401 ( 3.7A) ANP A 401 ( 4.3A) ANP A 401 (-3.2A) CHU A 403 (-4.2A) MG A 402 ( 2.9A) ANP A 401 (-4.8A)	0.76A	1fmoE-3wigA: 24.2	1fmoE-3wigA: 27.45
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1XBB_A_STIA1_1 (TYROSINE-PROTEIN KINASE SYK)	3wig	DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (Homo sapiens)	6 / 9	LEU A 75 VAL A 83 ALA A 96 MET A 144 GLY A 150 LEU A 198	ANP A 401 (-3.8A) ANP A 401 ( 4.3A) ANP A 401 (-3.2A) CHU A 403 (-3.8A) ANP A 401 ( 4.3A) ANP A 401 (-4.8A)	0.51A	1xbbA-3wigA: 23.2	1xbbA-3wigA: 25.38
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1XKK_A_FMMA91_1 (EPIDERMAL GROWTH FACTOR RECEPTOR)	3wig	DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (Homo sapiens)	5 / 12	ALA A 96 GLY A 150 LEU A 198 ASP A 209 PHE A 210	ANP A 401 (-3.2A) ANP A 401 ( 4.3A) ANP A 401 (-4.8A) MG A 402 (-3.2A) CHU A 403 (-3.8A)	0.43A	1xkkA-3wigA: 24.5	1xkkA-3wigA: 25.00
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2EVA_A_ADNA498_1 (TAK1 KINASE - TAB1 CHIMERA FUSION PROTEIN)	3wig	DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (Homo sapiens)	6 / 11	GLY A 76 VAL A 83 ALA A 96 MET A 144 SER A 151 LEU A 198	ANP A 401 ( 3.7A) ANP A 401 ( 4.3A) ANP A 401 (-3.2A) CHU A 403 (-3.8A) ANP A 401 (-3.3A) ANP A 401 (-4.8A)	0.59A	2evaA-3wigA: 24.3	2evaA-3wigA: 29.31
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2FUM_B_MIXB1539_1 (PROBABLE SERINE/THREONINE-PRO TEIN KINASE PKNB)	3wig	DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (Homo sapiens)	7 / 12	LEU A 75 GLY A 76 VAL A 83 ALA A 96 MET A 144 LYS A 193 ASN A 196	ANP A 401 (-3.8A) ANP A 401 ( 3.7A) ANP A 401 ( 4.3A) ANP A 401 (-3.2A) CHU A 403 (-3.8A) ANP A 401 (-3.0A) MG A 402 ( 2.9A)	0.99A	2fumB-3wigA: 25.7	2fumB-3wigA: 26.82
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2FUM_C_MIXC2539_1 (PROBABLE SERINE/THREONINE-PRO TEIN KINASE PKNB)	3wig	DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (Homo sapiens)	6 / 12	LEU A 75 VAL A 83 ALA A 96 MET A 144 ASN A 196 ASP A 209	ANP A 401 (-3.8A) ANP A 401 ( 4.3A) ANP A 401 (-3.2A) CHU A 403 (-3.8A) MG A 402 ( 2.9A) MG A 402 (-3.2A)	0.79A	2fumC-3wigA: 25.6	2fumC-3wigA: 26.82
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2FUM_D_MIXD3539_1 (PROBABLE SERINE/THREONINE-PRO TEIN KINASE PKNB)	3wig	DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (Homo sapiens)	8 / 12	LEU A 75 GLY A 76 GLY A 78 VAL A 83 ALA A 96 MET A 144 LYS A 193 ASN A 196	ANP A 401 (-3.8A) ANP A 401 ( 3.7A) ANP A 401 (-3.3A) ANP A 401 ( 4.3A) ANP A 401 (-3.2A) CHU A 403 (-3.8A) ANP A 401 (-3.0A) MG A 402 ( 2.9A)	1.15A	2fumD-3wigA: 26.1	2fumD-3wigA: 26.82
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2FUM_D_MIXD3539_1 (PROBABLE SERINE/THREONINE-PRO TEIN KINASE PKNB)	3wig	DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (Homo sapiens)	7 / 12	LEU A 75 VAL A 83 ALA A 96 MET A 144 LYS A 193 ASN A 196 ASP A 209	ANP A 401 (-3.8A) ANP A 401 ( 4.3A) ANP A 401 (-3.2A) CHU A 403 (-3.8A) ANP A 401 (-3.0A) MG A 402 ( 2.9A) MG A 402 (-3.2A)	0.84A	2fumD-3wigA: 26.1	2fumD-3wigA: 26.82
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2GQG_B_1N1B502_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1)	3wig	DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (Homo sapiens)	7 / 12	LEU A 75 VAL A 83 ALA A 96 VAL A 128 ILE A 142 GLY A 150 LEU A 198	ANP A 401 (-3.8A) ANP A 401 ( 4.3A) ANP A 401 (-3.2A) CHU A 403 (-4.2A) CHU A 403 (-3.8A) ANP A 401 ( 4.3A) ANP A 401 (-4.8A)	0.57A	2gqgB-3wigA: 22.7	2gqgB-3wigA: 25.48
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2HYY_A_STIA600_2 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1)	3wig	DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (Homo sapiens)	5 / 6	LEU A 75 LYS A 98 VAL A 212 VAL A 128 ILE A 142	ANP A 401 (-3.8A) ANP A 401 (-2.7A) CHU A 403 ( 4.0A) CHU A 403 (-4.2A) CHU A 403 (-3.8A)	1.19A	2hyyA-3wigA: 22.5	2hyyA-3wigA: 25.73
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2HYY_B_STIB600_2 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1)	3wig	DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (Homo sapiens)	4 / 6	LEU A 75 LYS A 98 VAL A 128 ILE A 142	ANP A 401 (-3.8A) ANP A 401 (-2.7A) CHU A 403 (-4.2A) CHU A 403 (-3.8A)	0.67A	2hyyB-3wigA: 22.5	2hyyB-3wigA: 25.73
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2ZVA_A_1N1A513_1 (TYROSINE-PROTEIN KINASE LYN)	3wig	DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (Homo sapiens)	8 / 12	LEU A 75 ALA A 96 LYS A 98 VAL A 128 ILE A 142 MET A 147 GLY A 150 LEU A 198	ANP A 401 (-3.8A) ANP A 401 (-3.2A) ANP A 401 (-2.7A) CHU A 403 (-4.2A) CHU A 403 (-3.8A) None ANP A 401 ( 4.3A) ANP A 401 (-4.8A)	0.66A	2zvaA-3wigA: 23.7	2zvaA-3wigA: 25.31
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3AOX_A_EMHA901_1 (ALK TYROSINE KINASE RECEPTOR)	3wig	DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (Homo sapiens)	7 / 10	LEU A 75 ALA A 96 LYS A 98 VAL A 128 MET A 147 GLY A 150 LEU A 198	ANP A 401 (-3.8A) ANP A 401 (-3.2A) ANP A 401 (-2.7A) CHU A 403 (-4.2A) None ANP A 401 ( 4.3A) ANP A 401 (-4.8A)	0.65A	3aoxA-3wigA: 22.8	3aoxA-3wigA: 24.33
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3BBT_B_FMMB91_1 (RECEPTOR TYROSINE-PROTEIN KINASE ERBB-4)	3wig	DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (Homo sapiens)	6 / 12	VAL A 83 ALA A 96 GLY A 150 LEU A 198 ASP A 209 PHE A 210	ANP A 401 ( 4.3A) ANP A 401 (-3.2A) ANP A 401 ( 4.3A) ANP A 401 (-4.8A) MG A 402 (-3.2A) CHU A 403 (-3.8A)	0.37A	3bbtB-3wigA: 17.4	3bbtB-3wigA: 25.84
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3BBT_D_FMMD91_1 (RECEPTOR TYROSINE-PROTEIN KINASE ERBB-4)	3wig	DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (Homo sapiens)	7 / 12	VAL A 83 ALA A 96 LYS A 98 GLY A 150 LEU A 198 ASP A 209 PHE A 210	ANP A 401 ( 4.3A) ANP A 401 (-3.2A) ANP A 401 (-2.7A) ANP A 401 ( 4.3A) ANP A 401 (-4.8A) MG A 402 (-3.2A) CHU A 403 (-3.8A)	0.56A	3bbtD-3wigA: 24.5	3bbtD-3wigA: 25.84
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3C7Q_A_XINA1172_1 (VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2)	3wig	DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (Homo sapiens)	7 / 12	LEU A 75 GLY A 76 ALA A 96 LYS A 98 VAL A 128 GLY A 149 LEU A 198	ANP A 401 (-3.8A) ANP A 401 ( 3.7A) ANP A 401 (-3.2A) ANP A 401 (-2.7A) CHU A 403 (-4.2A) None ANP A 401 (-4.8A)	0.90A	3c7qA-3wigA: 21.6	3c7qA-3wigA: 24.86
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3C7Q_A_XINA1172_1 (VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2)	3wig	DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (Homo sapiens)	8 / 12	LEU A 75 GLY A 76 ALA A 96 LYS A 98 VAL A 128 GLY A 150 LEU A 198 CYH A 208	ANP A 401 (-3.8A) ANP A 401 ( 3.7A) ANP A 401 (-3.2A) ANP A 401 (-2.7A) CHU A 403 (-4.2A) ANP A 401 ( 4.3A) ANP A 401 (-4.8A) CHU A 403 ( 3.7A)	1.10A	3c7qA-3wigA: 21.6	3c7qA-3wigA: 24.86
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3CS9_A_NILA600_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1)	3wig	DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (Homo sapiens)	5 / 10	LEU A 75 VAL A 83 LYS A 98 VAL A 128 ILE A 142	ANP A 401 (-3.8A) ANP A 401 ( 4.3A) ANP A 401 (-2.7A) CHU A 403 (-4.2A) CHU A 403 (-3.8A)	0.54A	3cs9A-3wigA: 22.4	3cs9A-3wigA: 25.57
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3CS9_B_NILB600_2 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1)	3wig	DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (Homo sapiens)	5 / 9	LEU A 75 VAL A 83 LYS A 98 VAL A 128 ILE A 142	ANP A 401 (-3.8A) ANP A 401 ( 4.3A) ANP A 401 (-2.7A) CHU A 403 (-4.2A) CHU A 403 (-3.8A)	0.57A	3cs9B-3wigA: 10.4	3cs9B-3wigA: 25.57
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3CS9_B_NILB600_2 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1)	3wig	DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (Homo sapiens)	5 / 9	LEU A 75 VAL A 83 VAL A 128 ILE A 142 LEU A 198	ANP A 401 (-3.8A) ANP A 401 ( 4.3A) CHU A 403 (-4.2A) CHU A 403 (-3.8A) ANP A 401 (-4.8A)	0.86A	3cs9B-3wigA: 10.4	3cs9B-3wigA: 25.57
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3CS9_C_NILC600_2 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1)	3wig	DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (Homo sapiens)	5 / 9	LEU A 75 VAL A 83 LYS A 98 VAL A 128 ILE A 142	ANP A 401 (-3.8A) ANP A 401 ( 4.3A) ANP A 401 (-2.7A) CHU A 403 (-4.2A) CHU A 403 (-3.8A)	0.59A	3cs9C-3wigA: 17.2	3cs9C-3wigA: 25.57
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3EYG_A_MI1A1_1 (TYROSINE-PROTEIN KINASE)	3wig	DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (Homo sapiens)	8 / 12	LEU A 75 GLY A 76 GLY A 78 VAL A 83 ALA A 96 LYS A 98 MET A 144 LEU A 198	ANP A 401 (-3.8A) ANP A 401 ( 3.7A) ANP A 401 (-3.3A) ANP A 401 ( 4.3A) ANP A 401 (-3.2A) ANP A 401 (-2.7A) CHU A 403 (-3.8A) ANP A 401 (-4.8A)	0.67A	3eygA-3wigA: 22.6	3eygA-3wigA: 26.67
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3EYG_A_MI1A1_1 (TYROSINE-PROTEIN KINASE)	3wig	DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (Homo sapiens)	8 / 12	LEU A 75 GLY A 76 GLY A 78 VAL A 83 ALA A 96 MET A 144 SER A 151 LEU A 198	ANP A 401 (-3.8A) ANP A 401 ( 3.7A) ANP A 401 (-3.3A) ANP A 401 ( 4.3A) ANP A 401 (-3.2A) CHU A 403 (-3.8A) ANP A 401 (-3.3A) ANP A 401 (-4.8A)	0.66A	3eygA-3wigA: 22.6	3eygA-3wigA: 26.67
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3FUP_B_MI1B1_1 (TYROSINE-PROTEIN KINASE JAK2)	3wig	DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (Homo sapiens)	7 / 12	LEU A 75 GLY A 76 GLY A 78 VAL A 83 ALA A 96 LYS A 98 MET A 144	ANP A 401 (-3.8A) ANP A 401 ( 3.7A) ANP A 401 (-3.3A) ANP A 401 ( 4.3A) ANP A 401 (-3.2A) ANP A 401 (-2.7A) CHU A 403 (-3.8A)	0.45A	3fupB-3wigA: 22.8	3fupB-3wigA: 28.83
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3FUP_B_MI1B1_1 (TYROSINE-PROTEIN KINASE JAK2)	3wig	DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (Homo sapiens)	7 / 12	LEU A 75 GLY A 76 GLY A 78 VAL A 83 ALA A 96 MET A 144 LEU A 198	ANP A 401 (-3.8A) ANP A 401 ( 3.7A) ANP A 401 (-3.3A) ANP A 401 ( 4.3A) ANP A 401 (-3.2A) CHU A 403 (-3.8A) ANP A 401 (-4.8A)	0.45A	3fupB-3wigA: 22.8	3fupB-3wigA: 28.83
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3G0E_A_B49A9000_1 (MAST/STEM CELL GROWTH FACTOR RECEPTOR)	3wig	DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (Homo sapiens)	7 / 11	LEU A 75 VAL A 83 ALA A 96 VAL A 128 GLY A 150 LEU A 198 CYH A 208	ANP A 401 (-3.8A) ANP A 401 ( 4.3A) ANP A 401 (-3.2A) CHU A 403 (-4.2A) ANP A 401 ( 4.3A) ANP A 401 (-4.8A) CHU A 403 ( 3.7A)	0.92A	3g0eA-3wigA: 21.3	3g0eA-3wigA: 24.52
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3G5D_A_1N1A1_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC)	3wig	DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (Homo sapiens)	7 / 12	LEU A 75 VAL A 83 ALA A 96 VAL A 128 ILE A 142 GLY A 150 LEU A 198	ANP A 401 (-3.8A) ANP A 401 ( 4.3A) ANP A 401 (-3.2A) CHU A 403 (-4.2A) CHU A 403 (-3.8A) ANP A 401 ( 4.3A) ANP A 401 (-4.8A)	0.60A	3g5dA-3wigA: 22.6	3g5dA-3wigA: 27.02
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3K54_A_1N1A1_1 (TYROSINE-PROTEIN KINASE BTK)	3wig	DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (Homo sapiens)	7 / 12	LEU A 75 ALA A 96 LYS A 98 VAL A 128 ILE A 142 GLY A 150 LEU A 198	ANP A 401 (-3.8A) ANP A 401 (-3.2A) ANP A 401 (-2.7A) CHU A 403 (-4.2A) CHU A 403 (-3.8A) ANP A 401 ( 4.3A) ANP A 401 (-4.8A)	0.63A	3k54A-3wigA: 22.7	3k54A-3wigA: 25.89
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3K5V_A_STIA2_2 (TYROSINE-PROTEIN KINASE ABL1)	3wig	DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (Homo sapiens)	4 / 6	LEU A 75 LYS A 98 VAL A 128 ILE A 142	ANP A 401 (-3.8A) ANP A 401 (-2.7A) CHU A 403 (-4.2A) CHU A 403 (-3.8A)	0.61A	3k5vA-3wigA: 21.6	3k5vA-3wigA: 25.94
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3K5V_B_STIB2_2 (TYROSINE-PROTEIN KINASE ABL1)	3wig	DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (Homo sapiens)	4 / 6	LEU A 75 LYS A 98 VAL A 128 ILE A 142	ANP A 401 (-3.8A) ANP A 401 (-2.7A) CHU A 403 (-4.2A) CHU A 403 (-3.8A)	0.63A	3k5vB-3wigA: 21.5	3k5vB-3wigA: 25.94
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3LXK_A_MI1A1125_1 (TYROSINE-PROTEIN KINASE JAK3)	3wig	DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (Homo sapiens)	7 / 12	LEU A 75 GLY A 76 VAL A 83 ALA A 96 LYS A 98 VAL A 128 MET A 144	ANP A 401 (-3.8A) ANP A 401 ( 3.7A) ANP A 401 ( 4.3A) ANP A 401 (-3.2A) ANP A 401 (-2.7A) CHU A 403 (-4.2A) CHU A 403 (-3.8A)	0.67A	3lxkA-3wigA: 22.3	3lxkA-3wigA: 29.07
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3MIY_A_B49A1_1 (TYROSINE-PROTEIN KINASE ITK/TSK)	3wig	DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (Homo sapiens)	7 / 11	ALA A 96 LYS A 98 VAL A 128 MET A 147 GLY A 150 LEU A 198 ASP A 209	ANP A 401 (-3.2A) ANP A 401 (-2.7A) CHU A 403 (-4.2A) None ANP A 401 ( 4.3A) ANP A 401 (-4.8A) MG A 402 (-3.2A)	0.75A	3miyA-3wigA: 24.2	3miyA-3wigA: 26.33
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3MSS_D_STID1_2 (TYROSINE-PROTEIN KINASE ABL1)	3wig	DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (Homo sapiens)	5 / 6	VAL A 83 LYS A 98 VAL A 212 VAL A 128 ILE A 142	ANP A 401 ( 4.3A) ANP A 401 (-2.7A) CHU A 403 ( 4.0A) CHU A 403 (-4.2A) CHU A 403 (-3.8A)	1.14A	3mssD-3wigA: 22.1	3mssD-3wigA: 25.94
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3OCT_A_1N1A663_1 (TYROSINE-PROTEIN KINASE BTK)	3wig	DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (Homo sapiens)	7 / 12	LEU A 75 VAL A 83 ALA A 96 LYS A 98 VAL A 128 GLY A 150 LEU A 198	ANP A 401 (-3.8A) ANP A 401 ( 4.3A) ANP A 401 (-3.2A) ANP A 401 (-2.7A) CHU A 403 (-4.2A) ANP A 401 ( 4.3A) ANP A 401 (-4.8A)	0.65A	3octA-3wigA: 22.9	3octA-3wigA: 27.04
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3OXZ_A_0LIA1_2 (TYROSINE-PROTEIN KINASE ABL1)	3wig	DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (Homo sapiens)	5 / 9	LEU A 75 VAL A 212 ILE A 142 MET A 147 LEU A 198	ANP A 401 (-3.8A) CHU A 403 ( 4.0A) CHU A 403 (-3.8A) None ANP A 401 (-4.8A)	1.18A	3oxzA-3wigA: 15.3	3oxzA-3wigA: 26.69
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3SXR_A_1N1A1_1 (CYTOPLASMIC TYROSINE-PROTEIN KINASE BMX)	3wig	DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (Homo sapiens)	7 / 12	LEU A 75 VAL A 83 ALA A 96 VAL A 128 ILE A 142 GLY A 150 LEU A 198	ANP A 401 (-3.8A) ANP A 401 ( 4.3A) ANP A 401 (-3.2A) CHU A 403 (-4.2A) CHU A 403 (-3.8A) ANP A 401 ( 4.3A) ANP A 401 (-4.8A)	0.52A	3sxrA-3wigA: 23.3	3sxrA-3wigA: 25.72
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3SXR_B_1N1B2_1 (CYTOPLASMIC TYROSINE-PROTEIN KINASE BMX)	3wig	DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (Homo sapiens)	6 / 12	LEU A 75 VAL A 83 ALA A 96 VAL A 128 GLY A 150 LEU A 198	ANP A 401 (-3.8A) ANP A 401 ( 4.3A) ANP A 401 (-3.2A) CHU A 403 (-4.2A) ANP A 401 ( 4.3A) ANP A 401 (-4.8A)	0.48A	3sxrB-3wigA: 22.9	3sxrB-3wigA: 25.72
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3UE4_A_DB8A601_1 (TYROSINE-PROTEIN KINASE ABL1)	3wig	DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (Homo sapiens)	8 / 12	LEU A 75 ALA A 96 LYS A 98 VAL A 128 ILE A 142 MET A 147 GLY A 150 LEU A 198	ANP A 401 (-3.8A) ANP A 401 (-3.2A) ANP A 401 (-2.7A) CHU A 403 (-4.2A) CHU A 403 (-3.8A) None ANP A 401 ( 4.3A) ANP A 401 (-4.8A)	0.66A	3ue4A-3wigA: 23.1	3ue4A-3wigA: 25.55
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3UE4_B_DB8B601_1 (TYROSINE-PROTEIN KINASE ABL1)	3wig	DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (Homo sapiens)	7 / 12	LEU A 75 VAL A 83 ALA A 96 VAL A 128 ILE A 142 GLY A 150 LEU A 198	ANP A 401 (-3.8A) ANP A 401 ( 4.3A) ANP A 401 (-3.2A) CHU A 403 (-4.2A) CHU A 403 (-3.8A) ANP A 401 ( 4.3A) ANP A 401 (-4.8A)	0.70A	3ue4B-3wigA: 23.1	3ue4B-3wigA: 25.55
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3WXO_A_NIZA802_1 (CATALASE-PEROXIDASE)	3wig	DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (Homo sapiens)	4 / 8	LEU A 102 ILE A 112 GLY A 214 ILE A 217	None None PG4 A 404 (-3.4A) CHU A 403 (-4.0A)	0.86A	3wxoA-3wigA: undetectable	3wxoA-3wigA: 18.26
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4AG8_A_AXIA2000_1 (VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2)	3wig	DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (Homo sapiens)	8 / 12	LEU A 75 VAL A 83 ALA A 96 LYS A 98 VAL A 128 GLY A 150 LEU A 198 CYH A 208	ANP A 401 (-3.8A) ANP A 401 ( 4.3A) ANP A 401 (-3.2A) ANP A 401 (-2.7A) CHU A 403 (-4.2A) ANP A 401 ( 4.3A) ANP A 401 (-4.8A) CHU A 403 ( 3.7A)	1.21A	4ag8A-3wigA: 22.2	4ag8A-3wigA: 24.57
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4AGD_A_B49A2000_1 (VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2)	3wig	DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (Homo sapiens)	6 / 11	LEU A 75 ALA A 96 LYS A 98 GLY A 150 LEU A 198 CYH A 208	ANP A 401 (-3.8A) ANP A 401 (-3.2A) ANP A 401 (-2.7A) ANP A 401 ( 4.3A) ANP A 401 (-4.8A) CHU A 403 ( 3.7A)	1.29A	4agdA-3wigA: 16.1	4agdA-3wigA: 22.48
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4AN2_A_EUIA1382_1 (DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1)	3wig	DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (Homo sapiens)	8 / 12	LYS A 98 LEU A 116 ILE A 142 ASP A 191 LYS A 193 ASN A 196 ASP A 209 GLY A 211	ANP A 401 (-2.7A) None CHU A 403 (-3.8A) CHU A 403 (-3.6A) ANP A 401 (-3.0A) MG A 402 ( 2.9A) MG A 402 (-3.2A) CHU A 403 ( 3.3A)	1.50A	4an2A-3wigA: 40.7	4an2A-3wigA: 94.21
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4AN2_A_EUIA1382_1 (DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1)	3wig	DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (Homo sapiens)	11 / 12	LYS A 98 LEU A 116 LEU A 119 ILE A 142 MET A 144 ASP A 191 LYS A 193 ASN A 196 ASP A 209 GLY A 211 VAL A 212	ANP A 401 (-2.7A) None CHU A 403 (-4.4A) CHU A 403 (-3.8A) CHU A 403 (-3.8A) CHU A 403 (-3.6A) ANP A 401 (-3.0A) MG A 402 ( 2.9A) MG A 402 (-3.2A) CHU A 403 ( 3.3A) CHU A 403 ( 4.0A)	0.48A	4an2A-3wigA: 40.7	4an2A-3wigA: 94.21
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4ANS_A_VGHA9000_1 (ALK TYROSINE KINASE RECEPTOR)	3wig	DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (Homo sapiens)	7 / 9	LEU A 75 VAL A 83 ALA A 96 MET A 144 MET A 147 GLY A 150 LEU A 198	ANP A 401 (-3.8A) ANP A 401 ( 4.3A) ANP A 401 (-3.2A) CHU A 403 (-3.8A) None ANP A 401 ( 4.3A) ANP A 401 (-4.8A)	0.44A	4ansA-3wigA: 22.9	4ansA-3wigA: 24.27
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4LMN_A_EUIA503_1 (DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1)	3wig	DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (Homo sapiens)	12 / 12	LYS A 98 LEU A 116 LEU A 119 ILE A 142 MET A 144 ASN A 196 ASP A 209 PHE A 210 GLY A 211 SER A 213 LEU A 216 MET A 220	ANP A 401 (-2.7A) None CHU A 403 (-4.4A) CHU A 403 (-3.8A) CHU A 403 (-3.8A) MG A 402 ( 2.9A) MG A 402 (-3.2A) CHU A 403 (-3.8A) CHU A 403 ( 3.3A) CHU A 403 (-4.7A) CHU A 403 (-4.1A) CHU A 403 (-3.6A)	0.42A	4lmnA-3wigA: 41.8	4lmnA-3wigA: 90.03
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4MXO_A_DB8A601_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC)	3wig	DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (Homo sapiens)	7 / 12	LEU A 75 VAL A 83 ALA A 96 LYS A 98 VAL A 128 ILE A 142 GLY A 150	ANP A 401 (-3.8A) ANP A 401 ( 4.3A) ANP A 401 (-3.2A) ANP A 401 (-2.7A) CHU A 403 (-4.2A) CHU A 403 (-3.8A) ANP A 401 ( 4.3A)	0.70A	4mxoA-3wigA: 22.1	4mxoA-3wigA: 27.33
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4MXO_B_DB8B601_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC)	3wig	DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (Homo sapiens)	8 / 12	LEU A 75 VAL A 83 ALA A 96 LYS A 98 VAL A 128 ILE A 142 GLY A 150 LEU A 198	ANP A 401 (-3.8A) ANP A 401 ( 4.3A) ANP A 401 (-3.2A) ANP A 401 (-2.7A) CHU A 403 (-4.2A) CHU A 403 (-3.8A) ANP A 401 ( 4.3A) ANP A 401 (-4.8A)	0.68A	4mxoB-3wigA: 22.2	4mxoB-3wigA: 27.33
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4MXX_A_DB8A601_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC)	3wig	DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (Homo sapiens)	7 / 12	LEU A 75 ALA A 96 LYS A 98 VAL A 128 ILE A 142 GLY A 150 LEU A 198	ANP A 401 (-3.8A) ANP A 401 (-3.2A) ANP A 401 (-2.7A) CHU A 403 (-4.2A) CHU A 403 (-3.8A) ANP A 401 ( 4.3A) ANP A 401 (-4.8A)	0.82A	4mxxA-3wigA: 22.1	4mxxA-3wigA: 27.33
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4MXX_B_DB8B601_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC)	3wig	DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (Homo sapiens)	8 / 12	LEU A 75 VAL A 83 ALA A 96 LYS A 98 VAL A 128 MET A 147 GLY A 150 LEU A 198	ANP A 401 (-3.8A) ANP A 401 ( 4.3A) ANP A 401 (-3.2A) ANP A 401 (-2.7A) CHU A 403 (-4.2A) None ANP A 401 ( 4.3A) ANP A 401 (-4.8A)	0.70A	4mxxB-3wigA: 16.3	4mxxB-3wigA: 27.33
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4WBO_B_ANWB601_0 (RHODOPSIN KINASE)	3wig	DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (Homo sapiens)	4 / 8	LEU A 75 ALA A 96 MET A 144 LEU A 198	ANP A 401 (-3.8A) ANP A 401 (-3.2A) CHU A 403 (-3.8A) ANP A 401 (-4.8A)	0.54A	4wboB-3wigA: 7.7	4wboB-3wigA: 20.54
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4WBO_C_ANWC601_0 (RHODOPSIN KINASE)	3wig	DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (Homo sapiens)	5 / 6	LEU A 75 ALA A 96 MET A 144 MET A 147 LEU A 198	ANP A 401 (-3.8A) ANP A 401 (-3.2A) CHU A 403 (-3.8A) None ANP A 401 (-4.8A)	0.57A	4wboC-3wigA: 23.2	4wboC-3wigA: 20.54
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4XEY_A_1N1A601_1 (TYROSINE-PROTEIN KINASE ABL1)	3wig	DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (Homo sapiens)	8 / 12	LEU A 75 VAL A 83 ALA A 96 LYS A 98 VAL A 128 ILE A 142 GLY A 150 LEU A 198	ANP A 401 (-3.8A) ANP A 401 ( 4.3A) ANP A 401 (-3.2A) ANP A 401 (-2.7A) CHU A 403 (-4.2A) CHU A 403 (-3.8A) ANP A 401 ( 4.3A) ANP A 401 (-4.8A)	0.64A	4xeyA-3wigA: 23.5	4xeyA-3wigA: 24.14
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4XEY_B_1N1B601_1 (TYROSINE-PROTEIN KINASE ABL1)	3wig	DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (Homo sapiens)	7 / 12	LEU A 75 VAL A 83 LYS A 98 VAL A 128 ILE A 142 GLY A 150 LEU A 198	ANP A 401 (-3.8A) ANP A 401 ( 4.3A) ANP A 401 (-2.7A) CHU A 403 (-4.2A) CHU A 403 (-3.8A) ANP A 401 ( 4.3A) ANP A 401 (-4.8A)	0.61A	4xeyB-3wigA: 23.2	4xeyB-3wigA: 24.14
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4XEY_B_1N1B601_1 (TYROSINE-PROTEIN KINASE ABL1)	3wig	DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (Homo sapiens)	7 / 12	VAL A 83 ALA A 96 LYS A 98 VAL A 128 ILE A 142 GLY A 150 LEU A 198	ANP A 401 ( 4.3A) ANP A 401 (-3.2A) ANP A 401 (-2.7A) CHU A 403 (-4.2A) CHU A 403 (-3.8A) ANP A 401 ( 4.3A) ANP A 401 (-4.8A)	0.45A	4xeyB-3wigA: 23.2	4xeyB-3wigA: 24.14
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5H2U_A_1N1A501_2 (PROTEIN-TYROSINE KINASE 6)	3wig	DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (Homo sapiens)	3 / 3	ILE A 142 MET A 147 ASP A 209	CHU A 403 (-3.8A) None MG A 402 (-3.2A)	0.69A	5h2uA-3wigA: 18.9	5h2uA-3wigA: 29.94
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5H2U_B_1N1B501_1 (PROTEIN-TYROSINE KINASE 6)	3wig	DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (Homo sapiens)	7 / 12	LEU A 75 VAL A 83 ALA A 96 ILE A 142 GLY A 150 LEU A 198 ASP A 209	ANP A 401 (-3.8A) ANP A 401 ( 4.3A) ANP A 401 (-3.2A) CHU A 403 (-3.8A) ANP A 401 ( 4.3A) ANP A 401 (-4.8A) MG A 402 (-3.2A)	0.65A	5h2uB-3wigA: 26.2	5h2uB-3wigA: 29.94
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5H2U_C_1N1C501_1 (PROTEIN-TYROSINE KINASE 6)	3wig	DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (Homo sapiens)	7 / 12	LEU A 75 ALA A 96 LYS A 98 ILE A 142 GLY A 150 LEU A 198 ASP A 209	ANP A 401 (-3.8A) ANP A 401 (-3.2A) ANP A 401 (-2.7A) CHU A 403 (-3.8A) ANP A 401 ( 4.3A) ANP A 401 (-4.8A) MG A 402 (-3.2A)	0.70A	5h2uC-3wigA: 26.1	5h2uC-3wigA: 29.94
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5H2U_D_1N1D504_1 (PROTEIN-TYROSINE KINASE 6)	3wig	DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (Homo sapiens)	7 / 12	LEU A 75 VAL A 83 ALA A 96 ILE A 142 GLY A 150 LEU A 198 ASP A 209	ANP A 401 (-3.8A) ANP A 401 ( 4.3A) ANP A 401 (-3.2A) CHU A 403 (-3.8A) ANP A 401 ( 4.3A) ANP A 401 (-4.8A) MG A 402 (-3.2A)	0.62A	5h2uD-3wigA: 26.0	5h2uD-3wigA: 29.94
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5L2T_A_6ZZA900_1 (CYCLIN-DEPENDENT KINASE 6)	3wig	DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (Homo sapiens)	6 / 12	GLY A 76 VAL A 83 ALA A 96 VAL A 128 HIS A 146 LEU A 198	ANP A 401 ( 3.7A) ANP A 401 ( 4.3A) ANP A 401 (-3.2A) CHU A 403 (-4.2A) ANP A 401 ( 4.9A) ANP A 401 (-4.8A)	0.87A	5l2tA-3wigA: 7.2	5l2tA-3wigA: 31.83
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5LVN_A_ADNA402_1 (3-PHOSPHOINOSITIDE-D EPENDENT PROTEIN KINASE 1)	3wig	DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (Homo sapiens)	6 / 11	LEU A 75 GLY A 76 VAL A 83 ALA A 96 VAL A 128 LEU A 198	ANP A 401 (-3.8A) ANP A 401 ( 3.7A) ANP A 401 ( 4.3A) ANP A 401 (-3.2A) CHU A 403 (-4.2A) ANP A 401 (-4.8A)	0.62A	5lvnA-3wigA: 24.2	5lvnA-3wigA: 26.69
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5LW1_B_ADNB401_1 (MITOGEN-ACTIVATED PROTEIN KINASE 8)	3wig	DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (Homo sapiens)	5 / 9	GLY A 76 VAL A 83 ALA A 96 MET A 144 MET A 147	ANP A 401 ( 3.7A) ANP A 401 ( 4.3A) ANP A 401 (-3.2A) CHU A 403 (-3.8A) None	0.41A	5lw1B-3wigA: 21.4	5lw1B-3wigA: 15.28
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5LW1_E_ADNE401_1 (MITOGEN-ACTIVATED PROTEIN KINASE 8)	3wig	DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (Homo sapiens)	5 / 10	GLY A 76 VAL A 83 ALA A 96 MET A 144 MET A 147	ANP A 401 ( 3.7A) ANP A 401 ( 4.3A) ANP A 401 (-3.2A) CHU A 403 (-3.8A) None	0.42A	5lw1E-3wigA: 21.3	5lw1E-3wigA: 15.28
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5LW1_H_ADNH401_1 (MITOGEN-ACTIVATED PROTEIN KINASE 8)	3wig	DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (Homo sapiens)	5 / 9	GLY A 76 VAL A 83 ALA A 96 MET A 144 MET A 147	ANP A 401 ( 3.7A) ANP A 401 ( 4.3A) ANP A 401 (-3.2A) CHU A 403 (-3.8A) None	0.30A	5lw1H-3wigA: 21.4	5lw1H-3wigA: 15.28
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5MO4_A_NILA601_1 (TYROSINE-PROTEIN KINASE ABL1)	3wig	DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (Homo sapiens)	5 / 10	LEU A 75 VAL A 83 ILE A 142 MET A 147 GLY A 150	ANP A 401 (-3.8A) ANP A 401 ( 4.3A) CHU A 403 (-3.8A) None ANP A 401 ( 4.3A)	0.70A	5mo4A-3wigA: 18.8	5mo4A-3wigA: 21.69
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5MO4_A_NILA601_1 (TYROSINE-PROTEIN KINASE ABL1)	3wig	DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (Homo sapiens)	5 / 10	LEU A 75 VAL A 83 LYS A 98 ILE A 142 GLY A 149	ANP A 401 (-3.8A) ANP A 401 ( 4.3A) ANP A 401 (-2.7A) CHU A 403 (-3.8A) None	0.67A	5mo4A-3wigA: 18.8	5mo4A-3wigA: 21.69
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5N3H_A_NCAA401_0 (CAMP-DEPENDENT PROTEIN KINASE CATALYTIC SUBUNIT ALPHA)	3wig	DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (Homo sapiens)	6 / 10	LEU A 75 VAL A 83 ALA A 96 VAL A 128 MET A 144 LEU A 198	ANP A 401 (-3.8A) ANP A 401 ( 4.3A) ANP A 401 (-3.2A) CHU A 403 (-4.2A) CHU A 403 (-3.8A) ANP A 401 (-4.8A)	0.84A	5n3hA-3wigA: 24.2	5n3hA-3wigA: 27.37
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5P9I_A_1E8A701_1 (TYROSINE-PROTEIN KINASE BTK)	3wig	DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (Homo sapiens)	7 / 12	VAL A 83 ALA A 96 LYS A 98 ILE A 142 GLY A 150 LEU A 198 PHE A 210	ANP A 401 ( 4.3A) ANP A 401 (-3.2A) ANP A 401 (-2.7A) CHU A 403 (-3.8A) ANP A 401 ( 4.3A) ANP A 401 (-4.8A) CHU A 403 (-3.8A)	0.53A	5p9iA-3wigA: 25.7	5p9iA-3wigA: 26.20
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5YU9_A_1E8A1101_1 (EPIDERMAL GROWTH FACTOR RECEPTOR)	3wig	DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (Homo sapiens)	8 / 12	LEU A 75 GLY A 76 VAL A 83 ALA A 96 LYS A 98 MET A 144 LEU A 198 ASP A 209	ANP A 401 (-3.8A) ANP A 401 ( 3.7A) ANP A 401 ( 4.3A) ANP A 401 (-3.2A) ANP A 401 (-2.7A) CHU A 403 (-3.8A) ANP A 401 (-4.8A) MG A 402 (-3.2A)	0.83A	5yu9A-3wigA: 23.4	5yu9A-3wigA: 16.55
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5YU9_B_1E8B1101_1 (EPIDERMAL GROWTH FACTOR RECEPTOR)	3wig	DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (Homo sapiens)	7 / 12	GLY A 76 VAL A 83 ALA A 96 LYS A 98 MET A 144 ASP A 153 LEU A 198	ANP A 401 ( 3.7A) ANP A 401 ( 4.3A) ANP A 401 (-3.2A) ANP A 401 (-2.7A) CHU A 403 (-3.8A) None ANP A 401 (-4.8A)	1.27A	5yu9B-3wigA: 23.3	5yu9B-3wigA: 16.55
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5YU9_B_1E8B1101_1 (EPIDERMAL GROWTH FACTOR RECEPTOR)	3wig	DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (Homo sapiens)	7 / 12	GLY A 76 VAL A 83 ALA A 96 LYS A 98 MET A 144 LEU A 198 ASP A 209	ANP A 401 ( 3.7A) ANP A 401 ( 4.3A) ANP A 401 (-3.2A) ANP A 401 (-2.7A) CHU A 403 (-3.8A) ANP A 401 (-4.8A) MG A 402 (-3.2A)	0.81A	5yu9B-3wigA: 23.3	5yu9B-3wigA: 16.55
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5YU9_C_1E8C1101_1 (EPIDERMAL GROWTH FACTOR RECEPTOR)	3wig	DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (Homo sapiens)	6 / 12	VAL A 83 ALA A 96 LYS A 98 MET A 144 GLY A 150 ASP A 209	ANP A 401 ( 4.3A) ANP A 401 (-3.2A) ANP A 401 (-2.7A) CHU A 403 (-3.8A) ANP A 401 ( 4.3A) MG A 402 (-3.2A)	0.76A	5yu9C-3wigA: 23.4	5yu9C-3wigA: 16.55
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5YU9_D_1E8D1101_1 (EPIDERMAL GROWTH FACTOR RECEPTOR)	3wig	DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (Homo sapiens)	7 / 12	VAL A 83 ALA A 96 LYS A 98 MET A 144 GLY A 150 ASP A 153 LEU A 198	ANP A 401 ( 4.3A) ANP A 401 (-3.2A) ANP A 401 (-2.7A) CHU A 403 (-3.8A) ANP A 401 ( 4.3A) None ANP A 401 (-4.8A)	1.31A	5yu9D-3wigA: 24.0	5yu9D-3wigA: 16.55
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6FNM_A_1N1A1001_1 (-)	3wig	DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (Homo sapiens)	7 / 12	VAL A 83 ALA A 96 LYS A 98 ILE A 142 MET A 147 GLY A 150 LEU A 198	ANP A 401 ( 4.3A) ANP A 401 (-3.2A) ANP A 401 (-2.7A) CHU A 403 (-3.8A) None ANP A 401 ( 4.3A) ANP A 401 (-4.8A)	0.43A	6fnmA-3wigA: 23.4	6fnmA-3wigA: 26.23

[["DrReposER ID","Desc.","Hit PDB","Hit molecule","Hit organism","Res. no.","Interface","HETATM","RMSD","Z-score","Seq ID"],["1FMO_E_ADNE351_1","CAMP-DEPENDENT PROTEIN KINASE","3wig","DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1","Homo sapiens",7,"LEU A  75;GLY A  76;VAL A  83;ALA A  96;VAL A 128;ASN A 196;LEU A 198","ANP A 401 (-3.8A);ANP A 401 ( 3.7A);ANP A 401 ( 4.3A);ANP A 401 (-3.2A);CHU A 403 (-4.2A); MG A 402 ( 2.9A);ANP A 401 (-4.8A)","0.76A","1fmoE-3wigA:24.2",null],["1XBB_A_STIA1_1","TYROSINE-PROTEIN KINASE SYK","3wig","DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1","Homo sapiens",6,"LEU A  75;VAL A  83;ALA A  96;MET A 144;GLY A 150;LEU A 198","ANP A 401 (-3.8A);ANP A 401 ( 4.3A);ANP A 401 (-3.2A);CHU A 403 (-3.8A);ANP A 401 ( 4.3A);ANP A 401 (-4.8A)","0.51A","1xbbA-3wigA:23.2","1fmoE-3wigA:27.45"],["1XKK_A_FMMA91_1","EPIDERMAL GROWTH FACTOR RECEPTOR","3wig","DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1","Homo sapiens",5,"ALA A  96;GLY A 150;LEU A 198;ASP A 209;PHE A 210","ANP A 401 (-3.2A);ANP A 401 ( 4.3A);ANP A 401 (-4.8A); MG A 402 (-3.2A);CHU A 403 (-3.8A)","0.43A","1xkkA-3wigA:24.5","1xbbA-3wigA:25.38"],["2EVA_A_ADNA498_1","TAK1 KINASE - TAB1 CHIMERA FUSION PROTEIN","3wig","DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1","Homo sapiens",6,"GLY A  76;VAL A  83;ALA A  96;MET A 144;SER A 151;LEU A 198","ANP A 401 ( 3.7A);ANP A 401 ( 4.3A);ANP A 401 (-3.2A);CHU A 403 (-3.8A);ANP A 401 (-3.3A);ANP A 401 (-4.8A)","0.59A","2evaA-3wigA:24.3","1xkkA-3wigA:25.00"],["2FUM_B_MIXB1539_1","PROBABLE SERINE\/THREONINE-PROTEIN KINASE PKNB","3wig","DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1","Homo sapiens",7,"LEU A  75;GLY A  76;VAL A  83;ALA A  96;MET A 144;LYS A 193;ASN A 196","ANP A 401 (-3.8A);ANP A 401 ( 3.7A);ANP A 401 ( 4.3A);ANP A 401 (-3.2A);CHU A 403 (-3.8A);ANP A 401 (-3.0A); MG A 402 ( 2.9A)","0.99A","2fumB-3wigA:25.7","2evaA-3wigA:29.31"],["2FUM_C_MIXC2539_1","PROBABLE SERINE\/THREONINE-PROTEIN KINASE PKNB","3wig","DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1","Homo sapiens",6,"LEU A  75;VAL A  83;ALA A  96;MET A 144;ASN A 196;ASP A 209","ANP A 401 (-3.8A);ANP A 401 ( 4.3A);ANP A 401 (-3.2A);CHU A 403 (-3.8A); MG A 402 ( 2.9A); MG A 402 (-3.2A)","0.79A","2fumC-3wigA:25.6","2fumB-3wigA:26.82"],["2FUM_D_MIXD3539_1","PROBABLE SERINE\/THREONINE-PROTEIN KINASE PKNB","3wig","DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1","Homo sapiens",8,"LEU A  75;GLY A  76;GLY A  78;VAL A  83;ALA A  96;MET A 144;LYS A 193;ASN A 196","ANP A 401 (-3.8A);ANP A 401 ( 3.7A);ANP A 401 (-3.3A);ANP A 401 ( 4.3A);ANP A 401 (-3.2A);CHU A 403 (-3.8A);ANP A 401 (-3.0A); MG A 402 ( 2.9A)","1.15A","2fumD-3wigA:26.1","2fumC-3wigA:26.82"],["2FUM_D_MIXD3539_1","PROBABLE SERINE\/THREONINE-PROTEIN KINASE PKNB","3wig","DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1","Homo sapiens",7,"LEU A  75;VAL A  83;ALA A  96;MET A 144;LYS A 193;ASN A 196;ASP A 209","ANP A 401 (-3.8A);ANP A 401 ( 4.3A);ANP A 401 (-3.2A);CHU A 403 (-3.8A);ANP A 401 (-3.0A); MG A 402 ( 2.9A); MG A 402 (-3.2A)","0.84A","2fumD-3wigA:26.1","2fumD-3wigA:26.82"],["2GQG_B_1N1B502_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","3wig","DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1","Homo sapiens",7,"LEU A  75;VAL A  83;ALA A  96;VAL A 128;ILE A 142;GLY A 150;LEU A 198","ANP A 401 (-3.8A);ANP A 401 ( 4.3A);ANP A 401 (-3.2A);CHU A 403 (-4.2A);CHU A 403 (-3.8A);ANP A 401 ( 4.3A);ANP A 401 (-4.8A)","0.57A","2gqgB-3wigA:22.7","2fumD-3wigA:26.82"],["2HYY_A_STIA600_2","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","3wig","DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1","Homo sapiens",5,"LEU A  75;LYS A  98;VAL A 212;VAL A 128;ILE A 142","ANP A 401 (-3.8A);ANP A 401 (-2.7A);CHU A 403 ( 4.0A);CHU A 403 (-4.2A);CHU A 403 (-3.8A)","1.19A","2hyyA-3wigA:22.5","2gqgB-3wigA:25.48"],["2HYY_B_STIB600_2","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","3wig","DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1","Homo sapiens",4,"LEU A  75;LYS A  98;VAL A 128;ILE A 142","ANP A 401 (-3.8A);ANP A 401 (-2.7A);CHU A 403 (-4.2A);CHU A 403 (-3.8A)","0.67A","2hyyB-3wigA:22.5","2hyyA-3wigA:25.73"],["2ZVA_A_1N1A513_1","TYROSINE-PROTEIN KINASE LYN","3wig","DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1","Homo sapiens",8,"LEU A  75;ALA A  96;LYS A  98;VAL A 128;ILE A 142;MET A 147;GLY A 150;LEU A 198","ANP A 401 (-3.8A);ANP A 401 (-3.2A);ANP A 401 (-2.7A);CHU A 403 (-4.2A);CHU A 403 (-3.8A);None;ANP A 401 ( 4.3A);ANP A 401 (-4.8A)","0.66A","2zvaA-3wigA:23.7","2hyyB-3wigA:25.73"],["3AOX_A_EMHA901_1","ALK TYROSINE KINASE RECEPTOR","3wig","DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1","Homo sapiens",7,"LEU A  75;ALA A  96;LYS A  98;VAL A 128;MET A 147;GLY A 150;LEU A 198","ANP A 401 (-3.8A);ANP A 401 (-3.2A);ANP A 401 (-2.7A);CHU A 403 (-4.2A);None;ANP A 401 ( 4.3A);ANP A 401 (-4.8A)","0.65A","3aoxA-3wigA:22.8","2zvaA-3wigA:25.31"],["3BBT_B_FMMB91_1","RECEPTOR TYROSINE-PROTEIN KINASE ERBB-4","3wig","DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1","Homo sapiens",6,"VAL A  83;ALA A  96;GLY A 150;LEU A 198;ASP A 209;PHE A 210","ANP A 401 ( 4.3A);ANP A 401 (-3.2A);ANP A 401 ( 4.3A);ANP A 401 (-4.8A); MG A 402 (-3.2A);CHU A 403 (-3.8A)","0.37A","3bbtB-3wigA:17.4","3aoxA-3wigA:24.33"],["3BBT_D_FMMD91_1","RECEPTOR TYROSINE-PROTEIN KINASE ERBB-4","3wig","DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1","Homo sapiens",7,"VAL A  83;ALA A  96;LYS A  98;GLY A 150;LEU A 198;ASP A 209;PHE A 210","ANP A 401 ( 4.3A);ANP A 401 (-3.2A);ANP A 401 (-2.7A);ANP A 401 ( 4.3A);ANP A 401 (-4.8A); MG A 402 (-3.2A);CHU A 403 (-3.8A)","0.56A","3bbtD-3wigA:24.5","3bbtB-3wigA:25.84"],["3C7Q_A_XINA1172_1","VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2","3wig","DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1","Homo sapiens",7,"LEU A  75;GLY A  76;ALA A  96;LYS A  98;VAL A 128;GLY A 149;LEU A 198","ANP A 401 (-3.8A);ANP A 401 ( 3.7A);ANP A 401 (-3.2A);ANP A 401 (-2.7A);CHU A 403 (-4.2A);None;ANP A 401 (-4.8A)","0.90A","3c7qA-3wigA:21.6","3bbtD-3wigA:25.84"],["3C7Q_A_XINA1172_1","VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2","3wig","DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1","Homo sapiens",8,"LEU A  75;GLY A  76;ALA A  96;LYS A  98;VAL A 128;GLY A 150;LEU A 198;CYH A 208","ANP A 401 (-3.8A);ANP A 401 ( 3.7A);ANP A 401 (-3.2A);ANP A 401 (-2.7A);CHU A 403 (-4.2A);ANP A 401 ( 4.3A);ANP A 401 (-4.8A);CHU A 403 ( 3.7A)","1.10A","3c7qA-3wigA:21.6","3c7qA-3wigA:24.86"],["3CS9_A_NILA600_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","3wig","DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1","Homo sapiens",5,"LEU A  75;VAL A  83;LYS A  98;VAL A 128;ILE A 142","ANP A 401 (-3.8A);ANP A 401 ( 4.3A);ANP A 401 (-2.7A);CHU A 403 (-4.2A);CHU A 403 (-3.8A)","0.54A","3cs9A-3wigA:22.4","3c7qA-3wigA:24.86"],["3CS9_B_NILB600_2","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","3wig","DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1","Homo sapiens",5,"LEU A  75;VAL A  83;LYS A  98;VAL A 128;ILE A 142","ANP A 401 (-3.8A);ANP A 401 ( 4.3A);ANP A 401 (-2.7A);CHU A 403 (-4.2A);CHU A 403 (-3.8A)","0.57A","3cs9B-3wigA:10.4","3cs9A-3wigA:25.57"],["3CS9_B_NILB600_2","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","3wig","DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1","Homo sapiens",5,"LEU A  75;VAL A  83;VAL A 128;ILE A 142;LEU A 198","ANP A 401 (-3.8A);ANP A 401 ( 4.3A);CHU A 403 (-4.2A);CHU A 403 (-3.8A);ANP A 401 (-4.8A)","0.86A","3cs9B-3wigA:10.4","3cs9B-3wigA:25.57"],["3CS9_C_NILC600_2","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","3wig","DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1","Homo sapiens",5,"LEU A  75;VAL A  83;LYS A  98;VAL A 128;ILE A 142","ANP A 401 (-3.8A);ANP A 401 ( 4.3A);ANP A 401 (-2.7A);CHU A 403 (-4.2A);CHU A 403 (-3.8A)","0.59A","3cs9C-3wigA:17.2","3cs9B-3wigA:25.57"],["3EYG_A_MI1A1_1","TYROSINE-PROTEIN KINASE","3wig","DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1","Homo sapiens",8,"LEU A  75;GLY A  76;GLY A  78;VAL A  83;ALA A  96;LYS A  98;MET A 144;LEU A 198","ANP A 401 (-3.8A);ANP A 401 ( 3.7A);ANP A 401 (-3.3A);ANP A 401 ( 4.3A);ANP A 401 (-3.2A);ANP A 401 (-2.7A);CHU A 403 (-3.8A);ANP A 401 (-4.8A)","0.67A","3eygA-3wigA:22.6","3cs9C-3wigA:25.57"],["3EYG_A_MI1A1_1","TYROSINE-PROTEIN KINASE","3wig","DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1","Homo sapiens",8,"LEU A  75;GLY A  76;GLY A  78;VAL A  83;ALA A  96;MET A 144;SER A 151;LEU A 198","ANP A 401 (-3.8A);ANP A 401 ( 3.7A);ANP A 401 (-3.3A);ANP A 401 ( 4.3A);ANP A 401 (-3.2A);CHU A 403 (-3.8A);ANP A 401 (-3.3A);ANP A 401 (-4.8A)","0.66A","3eygA-3wigA:22.6","3eygA-3wigA:26.67"],["3FUP_B_MI1B1_1","TYROSINE-PROTEIN KINASE JAK2","3wig","DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1","Homo sapiens",7,"LEU A  75;GLY A  76;GLY A  78;VAL A  83;ALA A  96;LYS A  98;MET A 144","ANP A 401 (-3.8A);ANP A 401 ( 3.7A);ANP A 401 (-3.3A);ANP A 401 ( 4.3A);ANP A 401 (-3.2A);ANP A 401 (-2.7A);CHU A 403 (-3.8A)","0.45A","3fupB-3wigA:22.8","3eygA-3wigA:26.67"],["3FUP_B_MI1B1_1","TYROSINE-PROTEIN KINASE JAK2","3wig","DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1","Homo sapiens",7,"LEU A  75;GLY A  76;GLY A  78;VAL A  83;ALA A  96;MET A 144;LEU A 198","ANP A 401 (-3.8A);ANP A 401 ( 3.7A);ANP A 401 (-3.3A);ANP A 401 ( 4.3A);ANP A 401 (-3.2A);CHU A 403 (-3.8A);ANP A 401 (-4.8A)","0.45A","3fupB-3wigA:22.8","3fupB-3wigA:28.83"],["3G0E_A_B49A9000_1","MAST\/STEM CELL GROWTH FACTOR RECEPTOR","3wig","DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1","Homo sapiens",7,"LEU A  75;VAL A  83;ALA A  96;VAL A 128;GLY A 150;LEU A 198;CYH A 208","ANP A 401 (-3.8A);ANP A 401 ( 4.3A);ANP A 401 (-3.2A);CHU A 403 (-4.2A);ANP A 401 ( 4.3A);ANP A 401 (-4.8A);CHU A 403 ( 3.7A)","0.92A","3g0eA-3wigA:21.3","3fupB-3wigA:28.83"],["3G5D_A_1N1A1_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC","3wig","DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1","Homo sapiens",7,"LEU A  75;VAL A  83;ALA A  96;VAL A 128;ILE A 142;GLY A 150;LEU A 198","ANP A 401 (-3.8A);ANP A 401 ( 4.3A);ANP A 401 (-3.2A);CHU A 403 (-4.2A);CHU A 403 (-3.8A);ANP A 401 ( 4.3A);ANP A 401 (-4.8A)","0.60A","3g5dA-3wigA:22.6","3g0eA-3wigA:24.52"],["3K54_A_1N1A1_1","TYROSINE-PROTEIN KINASE BTK","3wig","DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1","Homo sapiens",7,"LEU A  75;ALA A  96;LYS A  98;VAL A 128;ILE A 142;GLY A 150;LEU A 198","ANP A 401 (-3.8A);ANP A 401 (-3.2A);ANP A 401 (-2.7A);CHU A 403 (-4.2A);CHU A 403 (-3.8A);ANP A 401 ( 4.3A);ANP A 401 (-4.8A)","0.63A","3k54A-3wigA:22.7","3g5dA-3wigA:27.02"],["3K5V_A_STIA2_2","TYROSINE-PROTEIN KINASE ABL1","3wig","DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1","Homo sapiens",4,"LEU A  75;LYS A  98;VAL A 128;ILE A 142","ANP A 401 (-3.8A);ANP A 401 (-2.7A);CHU A 403 (-4.2A);CHU A 403 (-3.8A)","0.61A","3k5vA-3wigA:21.6","3k54A-3wigA:25.89"],["3K5V_B_STIB2_2","TYROSINE-PROTEIN KINASE ABL1","3wig","DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1","Homo sapiens",4,"LEU A  75;LYS A  98;VAL A 128;ILE A 142","ANP A 401 (-3.8A);ANP A 401 (-2.7A);CHU A 403 (-4.2A);CHU A 403 (-3.8A)","0.63A","3k5vB-3wigA:21.5","3k5vA-3wigA:25.94"],["3LXK_A_MI1A1125_1","TYROSINE-PROTEIN KINASE JAK3","3wig","DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1","Homo sapiens",7,"LEU A  75;GLY A  76;VAL A  83;ALA A  96;LYS A  98;VAL A 128;MET A 144","ANP A 401 (-3.8A);ANP A 401 ( 3.7A);ANP A 401 ( 4.3A);ANP A 401 (-3.2A);ANP A 401 (-2.7A);CHU A 403 (-4.2A);CHU A 403 (-3.8A)","0.67A","3lxkA-3wigA:22.3","3k5vB-3wigA:25.94"],["3MIY_A_B49A1_1","TYROSINE-PROTEIN KINASE ITK\/TSK","3wig","DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1","Homo sapiens",7,"ALA A  96;LYS A  98;VAL A 128;MET A 147;GLY A 150;LEU A 198;ASP A 209","ANP A 401 (-3.2A);ANP A 401 (-2.7A);CHU A 403 (-4.2A);None;ANP A 401 ( 4.3A);ANP A 401 (-4.8A); MG A 402 (-3.2A)","0.75A","3miyA-3wigA:24.2","3lxkA-3wigA:29.07"],["3MSS_D_STID1_2","TYROSINE-PROTEIN KINASE ABL1","3wig","DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1","Homo sapiens",5,"VAL A  83;LYS A  98;VAL A 212;VAL A 128;ILE A 142","ANP A 401 ( 4.3A);ANP A 401 (-2.7A);CHU A 403 ( 4.0A);CHU A 403 (-4.2A);CHU A 403 (-3.8A)","1.14A","3mssD-3wigA:22.1","3miyA-3wigA:26.33"],["3OCT_A_1N1A663_1","TYROSINE-PROTEIN KINASE BTK","3wig","DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1","Homo sapiens",7,"LEU A  75;VAL A  83;ALA A  96;LYS A  98;VAL A 128;GLY A 150;LEU A 198","ANP A 401 (-3.8A);ANP A 401 ( 4.3A);ANP A 401 (-3.2A);ANP A 401 (-2.7A);CHU A 403 (-4.2A);ANP A 401 ( 4.3A);ANP A 401 (-4.8A)","0.65A","3octA-3wigA:22.9","3mssD-3wigA:25.94"],["3OXZ_A_0LIA1_2","TYROSINE-PROTEIN KINASE ABL1","3wig","DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1","Homo sapiens",5,"LEU A  75;VAL A 212;ILE A 142;MET A 147;LEU A 198","ANP A 401 (-3.8A);CHU A 403 ( 4.0A);CHU A 403 (-3.8A);None;ANP A 401 (-4.8A)","1.18A","3oxzA-3wigA:15.3","3octA-3wigA:27.04"],["3SXR_A_1N1A1_1","CYTOPLASMIC TYROSINE-PROTEIN KINASE BMX","3wig","DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1","Homo sapiens",7,"LEU A  75;VAL A  83;ALA A  96;VAL A 128;ILE A 142;GLY A 150;LEU A 198","ANP A 401 (-3.8A);ANP A 401 ( 4.3A);ANP A 401 (-3.2A);CHU A 403 (-4.2A);CHU A 403 (-3.8A);ANP A 401 ( 4.3A);ANP A 401 (-4.8A)","0.52A","3sxrA-3wigA:23.3","3oxzA-3wigA:26.69"],["3SXR_B_1N1B2_1","CYTOPLASMIC TYROSINE-PROTEIN KINASE BMX","3wig","DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1","Homo sapiens",6,"LEU A  75;VAL A  83;ALA A  96;VAL A 128;GLY A 150;LEU A 198","ANP A 401 (-3.8A);ANP A 401 ( 4.3A);ANP A 401 (-3.2A);CHU A 403 (-4.2A);ANP A 401 ( 4.3A);ANP A 401 (-4.8A)","0.48A","3sxrB-3wigA:22.9","3sxrA-3wigA:25.72"],["3UE4_A_DB8A601_1","TYROSINE-PROTEIN KINASE ABL1","3wig","DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1","Homo sapiens",8,"LEU A  75;ALA A  96;LYS A  98;VAL A 128;ILE A 142;MET A 147;GLY A 150;LEU A 198","ANP A 401 (-3.8A);ANP A 401 (-3.2A);ANP A 401 (-2.7A);CHU A 403 (-4.2A);CHU A 403 (-3.8A);None;ANP A 401 ( 4.3A);ANP A 401 (-4.8A)","0.66A","3ue4A-3wigA:23.1","3sxrB-3wigA:25.72"],["3UE4_B_DB8B601_1","TYROSINE-PROTEIN KINASE ABL1","3wig","DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1","Homo sapiens",7,"LEU A  75;VAL A  83;ALA A  96;VAL A 128;ILE A 142;GLY A 150;LEU A 198","ANP A 401 (-3.8A);ANP A 401 ( 4.3A);ANP A 401 (-3.2A);CHU A 403 (-4.2A);CHU A 403 (-3.8A);ANP A 401 ( 4.3A);ANP A 401 (-4.8A)","0.70A","3ue4B-3wigA:23.1","3ue4A-3wigA:25.55"],["3WXO_A_NIZA802_1","CATALASE-PEROXIDASE","3wig","DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1","Homo sapiens",4,"LEU A 102;ILE A 112;GLY A 214;ILE A 217","None;None;PG4 A 404 (-3.4A);CHU A 403 (-4.0A)","0.86A","3wxoA-3wigA:undetectable","3ue4B-3wigA:25.55"],["4AG8_A_AXIA2000_1","VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2","3wig","DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1","Homo sapiens",8,"LEU A  75;VAL A  83;ALA A  96;LYS A  98;VAL A 128;GLY A 150;LEU A 198;CYH A 208","ANP A 401 (-3.8A);ANP A 401 ( 4.3A);ANP A 401 (-3.2A);ANP A 401 (-2.7A);CHU A 403 (-4.2A);ANP A 401 ( 4.3A);ANP A 401 (-4.8A);CHU A 403 ( 3.7A)","1.21A","4ag8A-3wigA:22.2","3wxoA-3wigA:18.26"],["4AGD_A_B49A2000_1","VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2","3wig","DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1","Homo sapiens",6,"LEU A  75;ALA A  96;LYS A  98;GLY A 150;LEU A 198;CYH A 208","ANP A 401 (-3.8A);ANP A 401 (-3.2A);ANP A 401 (-2.7A);ANP A 401 ( 4.3A);ANP A 401 (-4.8A);CHU A 403 ( 3.7A)","1.29A","4agdA-3wigA:16.1","4ag8A-3wigA:24.57"],["4AN2_A_EUIA1382_1","DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1","3wig","DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1","Homo sapiens",8,"LYS A  98;LEU A 116;ILE A 142;ASP A 191;LYS A 193;ASN A 196;ASP A 209;GLY A 211","ANP A 401 (-2.7A);None;CHU A 403 (-3.8A);CHU A 403 (-3.6A);ANP A 401 (-3.0A); MG A 402 ( 2.9A); MG A 402 (-3.2A);CHU A 403 ( 3.3A)","1.50A","4an2A-3wigA:40.7","4agdA-3wigA:22.48"],["4AN2_A_EUIA1382_1","DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1","3wig","DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1","Homo sapiens",11,"LYS A  98;LEU A 116;LEU A 119;ILE A 142;MET A 144;ASP A 191;LYS A 193;ASN A 196;ASP A 209;GLY A 211;VAL A 212","ANP A 401 (-2.7A);None;CHU A 403 (-4.4A);CHU A 403 (-3.8A);CHU A 403 (-3.8A);CHU A 403 (-3.6A);ANP A 401 (-3.0A); MG A 402 ( 2.9A); MG A 402 (-3.2A);CHU A 403 ( 3.3A);CHU A 403 ( 4.0A)","0.48A","4an2A-3wigA:40.7","4an2A-3wigA:94.21"],["4ANS_A_VGHA9000_1","ALK TYROSINE KINASE RECEPTOR","3wig","DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1","Homo sapiens",7,"LEU A  75;VAL A  83;ALA A  96;MET A 144;MET A 147;GLY A 150;LEU A 198","ANP A 401 (-3.8A);ANP A 401 ( 4.3A);ANP A 401 (-3.2A);CHU A 403 (-3.8A);None;ANP A 401 ( 4.3A);ANP A 401 (-4.8A)","0.44A","4ansA-3wigA:22.9","4an2A-3wigA:94.21"],["4LMN_A_EUIA503_1","DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1","3wig","DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1","Homo sapiens",12,"LYS A  98;LEU A 116;LEU A 119;ILE A 142;MET A 144;ASN A 196;ASP A 209;PHE A 210;GLY A 211;SER A 213;LEU A 216;MET A 220","ANP A 401 (-2.7A);None;CHU A 403 (-4.4A);CHU A 403 (-3.8A);CHU A 403 (-3.8A); MG A 402 ( 2.9A); MG A 402 (-3.2A);CHU A 403 (-3.8A);CHU A 403 ( 3.3A);CHU A 403 (-4.7A);CHU A 403 (-4.1A);CHU A 403 (-3.6A)","0.42A","4lmnA-3wigA:41.8","4ansA-3wigA:24.27"],["4MXO_A_DB8A601_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC","3wig","DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1","Homo sapiens",7,"LEU A  75;VAL A  83;ALA A  96;LYS A  98;VAL A 128;ILE A 142;GLY A 150","ANP A 401 (-3.8A);ANP A 401 ( 4.3A);ANP A 401 (-3.2A);ANP A 401 (-2.7A);CHU A 403 (-4.2A);CHU A 403 (-3.8A);ANP A 401 ( 4.3A)","0.70A","4mxoA-3wigA:22.1","4lmnA-3wigA:90.03"],["4MXO_B_DB8B601_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC","3wig","DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1","Homo sapiens",8,"LEU A  75;VAL A  83;ALA A  96;LYS A  98;VAL A 128;ILE A 142;GLY A 150;LEU A 198","ANP A 401 (-3.8A);ANP A 401 ( 4.3A);ANP A 401 (-3.2A);ANP A 401 (-2.7A);CHU A 403 (-4.2A);CHU A 403 (-3.8A);ANP A 401 ( 4.3A);ANP A 401 (-4.8A)","0.68A","4mxoB-3wigA:22.2","4mxoA-3wigA:27.33"],["4MXX_A_DB8A601_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC","3wig","DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1","Homo sapiens",7,"LEU A  75;ALA A  96;LYS A  98;VAL A 128;ILE A 142;GLY A 150;LEU A 198","ANP A 401 (-3.8A);ANP A 401 (-3.2A);ANP A 401 (-2.7A);CHU A 403 (-4.2A);CHU A 403 (-3.8A);ANP A 401 ( 4.3A);ANP A 401 (-4.8A)","0.82A","4mxxA-3wigA:22.1","4mxoB-3wigA:27.33"],["4MXX_B_DB8B601_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC","3wig","DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1","Homo sapiens",8,"LEU A  75;VAL A  83;ALA A  96;LYS A  98;VAL A 128;MET A 147;GLY A 150;LEU A 198","ANP A 401 (-3.8A);ANP A 401 ( 4.3A);ANP A 401 (-3.2A);ANP A 401 (-2.7A);CHU A 403 (-4.2A);None;ANP A 401 ( 4.3A);ANP A 401 (-4.8A)","0.70A","4mxxB-3wigA:16.3","4mxxA-3wigA:27.33"],["4WBO_B_ANWB601_0","RHODOPSIN KINASE","3wig","DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1","Homo sapiens",4,"LEU A  75;ALA A  96;MET A 144;LEU A 198","ANP A 401 (-3.8A);ANP A 401 (-3.2A);CHU A 403 (-3.8A);ANP A 401 (-4.8A)","0.54A","4wboB-3wigA:7.7","4mxxB-3wigA:27.33"],["4WBO_C_ANWC601_0","RHODOPSIN KINASE","3wig","DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1","Homo sapiens",5,"LEU A  75;ALA A  96;MET A 144;MET A 147;LEU A 198","ANP A 401 (-3.8A);ANP A 401 (-3.2A);CHU A 403 (-3.8A);None;ANP A 401 (-4.8A)","0.57A","4wboC-3wigA:23.2","4wboB-3wigA:20.54"],["4XEY_A_1N1A601_1","TYROSINE-PROTEIN KINASE ABL1","3wig","DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1","Homo sapiens",8,"LEU A  75;VAL A  83;ALA A  96;LYS A  98;VAL A 128;ILE A 142;GLY A 150;LEU A 198","ANP A 401 (-3.8A);ANP A 401 ( 4.3A);ANP A 401 (-3.2A);ANP A 401 (-2.7A);CHU A 403 (-4.2A);CHU A 403 (-3.8A);ANP A 401 ( 4.3A);ANP A 401 (-4.8A)","0.64A","4xeyA-3wigA:23.5","4wboC-3wigA:20.54"],["4XEY_B_1N1B601_1","TYROSINE-PROTEIN KINASE ABL1","3wig","DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1","Homo sapiens",7,"LEU A  75;VAL A  83;LYS A  98;VAL A 128;ILE A 142;GLY A 150;LEU A 198","ANP A 401 (-3.8A);ANP A 401 ( 4.3A);ANP A 401 (-2.7A);CHU A 403 (-4.2A);CHU A 403 (-3.8A);ANP A 401 ( 4.3A);ANP A 401 (-4.8A)","0.61A","4xeyB-3wigA:23.2","4xeyA-3wigA:24.14"],["4XEY_B_1N1B601_1","TYROSINE-PROTEIN KINASE ABL1","3wig","DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1","Homo sapiens",7,"VAL A  83;ALA A  96;LYS A  98;VAL A 128;ILE A 142;GLY A 150;LEU A 198","ANP A 401 ( 4.3A);ANP A 401 (-3.2A);ANP A 401 (-2.7A);CHU A 403 (-4.2A);CHU A 403 (-3.8A);ANP A 401 ( 4.3A);ANP A 401 (-4.8A)","0.45A","4xeyB-3wigA:23.2","4xeyB-3wigA:24.14"],["5H2U_A_1N1A501_2","PROTEIN-TYROSINE KINASE 6","3wig","DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1","Homo sapiens",3,"ILE A 142;MET A 147;ASP A 209","CHU A 403 (-3.8A);None; MG A 402 (-3.2A)","0.69A","5h2uA-3wigA:18.9","4xeyB-3wigA:24.14"],["5H2U_B_1N1B501_1","PROTEIN-TYROSINE KINASE 6","3wig","DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1","Homo sapiens",7,"LEU A  75;VAL A  83;ALA A  96;ILE A 142;GLY A 150;LEU A 198;ASP A 209","ANP A 401 (-3.8A);ANP A 401 ( 4.3A);ANP A 401 (-3.2A);CHU A 403 (-3.8A);ANP A 401 ( 4.3A);ANP A 401 (-4.8A); MG A 402 (-3.2A)","0.65A","5h2uB-3wigA:26.2","5h2uA-3wigA:29.94"],["5H2U_C_1N1C501_1","PROTEIN-TYROSINE KINASE 6","3wig","DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1","Homo sapiens",7,"LEU A  75;ALA A  96;LYS A  98;ILE A 142;GLY A 150;LEU A 198;ASP A 209","ANP A 401 (-3.8A);ANP A 401 (-3.2A);ANP A 401 (-2.7A);CHU A 403 (-3.8A);ANP A 401 ( 4.3A);ANP A 401 (-4.8A); MG A 402 (-3.2A)","0.70A","5h2uC-3wigA:26.1","5h2uB-3wigA:29.94"],["5H2U_D_1N1D504_1","PROTEIN-TYROSINE KINASE 6","3wig","DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1","Homo sapiens",7,"LEU A  75;VAL A  83;ALA A  96;ILE A 142;GLY A 150;LEU A 198;ASP A 209","ANP A 401 (-3.8A);ANP A 401 ( 4.3A);ANP A 401 (-3.2A);CHU A 403 (-3.8A);ANP A 401 ( 4.3A);ANP A 401 (-4.8A); MG A 402 (-3.2A)","0.62A","5h2uD-3wigA:26.0","5h2uC-3wigA:29.94"],["5L2T_A_6ZZA900_1","CYCLIN-DEPENDENT KINASE 6","3wig","DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1","Homo sapiens",6,"GLY A  76;VAL A  83;ALA A  96;VAL A 128;HIS A 146;LEU A 198","ANP A 401 ( 3.7A);ANP A 401 ( 4.3A);ANP A 401 (-3.2A);CHU A 403 (-4.2A);ANP A 401 ( 4.9A);ANP A 401 (-4.8A)","0.87A","5l2tA-3wigA:7.2","5h2uD-3wigA:29.94"],["5LVN_A_ADNA402_1","3-PHOSPHOINOSITIDE-DEPENDENT PROTEIN KINASE 1","3wig","DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1","Homo sapiens",6,"LEU A  75;GLY A  76;VAL A  83;ALA A  96;VAL A 128;LEU A 198","ANP A 401 (-3.8A);ANP A 401 ( 3.7A);ANP A 401 ( 4.3A);ANP A 401 (-3.2A);CHU A 403 (-4.2A);ANP A 401 (-4.8A)","0.62A","5lvnA-3wigA:24.2","5l2tA-3wigA:31.83"],["5LW1_B_ADNB401_1","MITOGEN-ACTIVATED PROTEIN KINASE 8","3wig","DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1","Homo sapiens",5,"GLY A  76;VAL A  83;ALA A  96;MET A 144;MET A 147","ANP A 401 ( 3.7A);ANP A 401 ( 4.3A);ANP A 401 (-3.2A);CHU A 403 (-3.8A);None","0.41A","5lw1B-3wigA:21.4","5lvnA-3wigA:26.69"],["5LW1_E_ADNE401_1","MITOGEN-ACTIVATED PROTEIN KINASE 8","3wig","DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1","Homo sapiens",5,"GLY A  76;VAL A  83;ALA A  96;MET A 144;MET A 147","ANP A 401 ( 3.7A);ANP A 401 ( 4.3A);ANP A 401 (-3.2A);CHU A 403 (-3.8A);None","0.42A","5lw1E-3wigA:21.3","5lw1B-3wigA:15.28"],["5LW1_H_ADNH401_1","MITOGEN-ACTIVATED PROTEIN KINASE 8","3wig","DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1","Homo sapiens",5,"GLY A  76;VAL A  83;ALA A  96;MET A 144;MET A 147","ANP A 401 ( 3.7A);ANP A 401 ( 4.3A);ANP A 401 (-3.2A);CHU A 403 (-3.8A);None","0.30A","5lw1H-3wigA:21.4","5lw1E-3wigA:15.28"],["5MO4_A_NILA601_1","TYROSINE-PROTEIN KINASE ABL1","3wig","DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1","Homo sapiens",5,"LEU A  75;VAL A  83;ILE A 142;MET A 147;GLY A 150","ANP A 401 (-3.8A);ANP A 401 ( 4.3A);CHU A 403 (-3.8A);None;ANP A 401 ( 4.3A)","0.70A","5mo4A-3wigA:18.8","5lw1H-3wigA:15.28"],["5MO4_A_NILA601_1","TYROSINE-PROTEIN KINASE ABL1","3wig","DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1","Homo sapiens",5,"LEU A  75;VAL A  83;LYS A  98;ILE A 142;GLY A 149","ANP A 401 (-3.8A);ANP A 401 ( 4.3A);ANP A 401 (-2.7A);CHU A 403 (-3.8A);None","0.67A","5mo4A-3wigA:18.8","5mo4A-3wigA:21.69"],["5N3H_A_NCAA401_0","CAMP-DEPENDENT PROTEIN KINASE CATALYTIC SUBUNIT ALPHA","3wig","DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1","Homo sapiens",6,"LEU A  75;VAL A  83;ALA A  96;VAL A 128;MET A 144;LEU A 198","ANP A 401 (-3.8A);ANP A 401 ( 4.3A);ANP A 401 (-3.2A);CHU A 403 (-4.2A);CHU A 403 (-3.8A);ANP A 401 (-4.8A)","0.84A","5n3hA-3wigA:24.2","5mo4A-3wigA:21.69"],["5P9I_A_1E8A701_1","TYROSINE-PROTEIN KINASE BTK","3wig","DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1","Homo sapiens",7,"VAL A  83;ALA A  96;LYS A  98;ILE A 142;GLY A 150;LEU A 198;PHE A 210","ANP A 401 ( 4.3A);ANP A 401 (-3.2A);ANP A 401 (-2.7A);CHU A 403 (-3.8A);ANP A 401 ( 4.3A);ANP A 401 (-4.8A);CHU A 403 (-3.8A)","0.53A","5p9iA-3wigA:25.7","5n3hA-3wigA:27.37"],["5YU9_A_1E8A1101_1","EPIDERMAL GROWTH FACTOR RECEPTOR","3wig","DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1","Homo sapiens",8,"LEU A  75;GLY A  76;VAL A  83;ALA A  96;LYS A  98;MET A 144;LEU A 198;ASP A 209","ANP A 401 (-3.8A);ANP A 401 ( 3.7A);ANP A 401 ( 4.3A);ANP A 401 (-3.2A);ANP A 401 (-2.7A);CHU A 403 (-3.8A);ANP A 401 (-4.8A); MG A 402 (-3.2A)","0.83A","5yu9A-3wigA:23.4","5p9iA-3wigA:26.20"],["5YU9_B_1E8B1101_1","EPIDERMAL GROWTH FACTOR RECEPTOR","3wig","DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1","Homo sapiens",7,"GLY A  76;VAL A  83;ALA A  96;LYS A  98;MET A 144;ASP A 153;LEU A 198","ANP A 401 ( 3.7A);ANP A 401 ( 4.3A);ANP A 401 (-3.2A);ANP A 401 (-2.7A);CHU A 403 (-3.8A);None;ANP A 401 (-4.8A)","1.27A","5yu9B-3wigA:23.3","5yu9A-3wigA:16.55"],["5YU9_B_1E8B1101_1","EPIDERMAL GROWTH FACTOR RECEPTOR","3wig","DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1","Homo sapiens",7,"GLY A  76;VAL A  83;ALA A  96;LYS A  98;MET A 144;LEU A 198;ASP A 209","ANP A 401 ( 3.7A);ANP A 401 ( 4.3A);ANP A 401 (-3.2A);ANP A 401 (-2.7A);CHU A 403 (-3.8A);ANP A 401 (-4.8A); MG A 402 (-3.2A)","0.81A","5yu9B-3wigA:23.3","5yu9B-3wigA:16.55"],["5YU9_C_1E8C1101_1","EPIDERMAL GROWTH FACTOR RECEPTOR","3wig","DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1","Homo sapiens",6,"VAL A  83;ALA A  96;LYS A  98;MET A 144;GLY A 150;ASP A 209","ANP A 401 ( 4.3A);ANP A 401 (-3.2A);ANP A 401 (-2.7A);CHU A 403 (-3.8A);ANP A 401 ( 4.3A); MG A 402 (-3.2A)","0.76A","5yu9C-3wigA:23.4","5yu9B-3wigA:16.55"],["5YU9_D_1E8D1101_1","EPIDERMAL GROWTH FACTOR RECEPTOR","3wig","DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1","Homo sapiens",7,"VAL A  83;ALA A  96;LYS A  98;MET A 144;GLY A 150;ASP A 153;LEU A 198","ANP A 401 ( 4.3A);ANP A 401 (-3.2A);ANP A 401 (-2.7A);CHU A 403 (-3.8A);ANP A 401 ( 4.3A);None;ANP A 401 (-4.8A)","1.31A","5yu9D-3wigA:24.0","5yu9C-3wigA:16.55"],["6FNM_A_1N1A1001_1","-","3wig","DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1","Homo sapiens",7,"VAL A  83;ALA A  96;LYS A  98;ILE A 142;MET A 147;GLY A 150;LEU A 198","ANP A 401 ( 4.3A);ANP A 401 (-3.2A);ANP A 401 (-2.7A);CHU A 403 (-3.8A);None;ANP A 401 ( 4.3A);ANP A 401 (-4.8A)","0.43A","6fnmA-3wigA:23.4","5yu9D-3wigA:16.55"]]